Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Pharmacogenet Genomics ; 31(9): 221-224, 2021 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-34320604

RESUMEN

A 34-year-old man with treatment-resistant schizophrenia and Gilbert's syndrome was treated with clozapine and found to have unusually slow and fluctuating metabolism of clozapine, resulting in difficulty achieving a well-tolerated and stable plasma clozapine level. Gilbert's syndrome is a relatively common (3-10% prevalence) genetic condition which results in altered hepatic metabolism. This case report demonstrates in vivo the finding of previous in-vitro research suggesting that the UGT1A1 7/7 mutation most commonly associated with Gilbert's syndrome may result in decreased clozapine excretion. Given evidence of an increased prevalence of Gilbert's syndrome in patients with schizophrenia, further investigation into this possible correlation may improve understanding and prediction of clozapine dosage.


Asunto(s)
Clozapina , Enfermedad de Gilbert , Adulto , Clozapina/efectos adversos , Enfermedad de Gilbert/genética , Glucuronosiltransferasa/genética , Humanos , Masculino , Esquizofrenia Resistente al Tratamiento
2.
Eur Arch Psychiatry Clin Neurosci ; 270(7): 921-932, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31802253

RESUMEN

Recent genome-wide association studies have demonstrated that the genetic burden associated with depression correlates with depression severity. Therefore, conducting genetic studies of patients at the most severe end of the depressive disorder spectrum, those with treatment-resistant depression and who are prescribed electroconvulsive therapy (ECT), could lead to a better understanding of the genetic underpinnings of depression. Despite ECT being one of the most effective forms of treatment for severe depressive disorders, it is usually placed at the end of treatment algorithms of current guidelines. This is perhaps because ECT has controlled risk and logistical demands including use of general anaesthesia and muscle relaxants and side-effects such as short-term memory impairment. Better understanding of the genetics and biology of ECT response and of cognitive side-effects could lead to more personalized treatment decisions. To enhance the understanding of the genomics of severe depression and ECT response, researchers and ECT providers from around the world and from various depression or ECT networks, but not limited to, such as the Psychiatric Genomics Consortium, the Clinical Alliance and Research in ECT, and the National Network of Depression Centers have formed the Genetics of ECT International Consortium (Gen-ECT-ic). Gen-ECT-ic will organize the largest clinical and genetic collection to date to study the genomics of severe depressive disorders and response to ECT, aiming for 30,000 patients worldwide using a GWAS approach. At this stage it will be the largest genomic study on treatment response in depression. Retrospective data abstraction and prospective data collection will be facilitated by a uniform data collection approach that is flexible and will incorporate data from many clinical practices. Gen-ECT-ic invites all ECT providers and researchers to join its efforts.


Asunto(s)
Conjuntos de Datos como Asunto , Trastorno Depresivo/genética , Trastorno Depresivo/terapia , Terapia Electroconvulsiva , Estudio de Asociación del Genoma Completo , Estudios Multicéntricos como Asunto , Recolección de Datos , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA